Business Context and Reporting Period
Company: Calidi Biotherapeutics, Inc. (CLDI)
Filing Type: Form 10-Q (Unaudited)
Period Ended: September 30, 2024
Business Overview: Calidi is a clinical-stage immuno-oncology company developing allogeneic stem cell-based and enveloped platforms to deliver oncolytic viruses for cancer treatment. Key product candidates include CLD-101 (NeuroNova) for High Grade Glioma and CLD-201 (SuperNova) for advanced solid tumors. The company has no approved products and has not generated revenue from product sales.
Key Financial Metrics
| Metric (in thousands) | Q3 2024 | Q3 2023 | 9M 2024 | 9M 2023 |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| Net Loss | $(5,069) | $(2,024) | $(18,061) | $(20,987) |
| Net Loss Per Share (Basic/Diluted) | $(0.65) | $(1.41) | $(3.54) | $(19.80) |
| Cash and Restricted Cash | $2,115 | $10,365 | $2,115 | $10,365 |
| Total Debt (Carrying Value) | $5,485 | $2,867 | $5,485 | $2,867 |
| Working Capital Deficit | $(9,358) | $(5,929) | $(9,358) | $(5,929) |
Note: Working Capital Deficit calculated as Total Current Assets ($2,221) minus Total Current Liabilities ($11,579).
Material Changes vs. Prior Period
- Operating Expenses: Total operating expenses decreased by 28% in Q3 2024 ($5.2M) compared to Q3 2023 ($7.2M), driven by reductions in drug manufacturing, lab supplies, and salaries. For the nine months ended September 30, 2024, total operating expenses decreased by 7% ($17.8M vs. $19.2M).
- Other Income/Expense: Net other income decreased significantly in Q3 2024 ($0.2M) compared to Q3 2023 ($5.2M). This was primarily due to a $4.9M decrease in gains from changes in fair value of debt, derivatives, and warrants, and a reduction in CIRM grant income.
- Debt Obligations: Total debt carrying value increased from $2.9M at year-end 2023 to $5.5M at September 30, 2024. This includes new convertible notes, term notes, and a promissory note, partially offset by repayments and conversions.
- Stock-Based Compensation: Stock-based compensation expense decreased to $0.7M in Q3 2024 from $1.1M in Q3 2023.
Guidance, Outlook, Risks, and Unusual Items
- Going Concern: Management has concluded that there is substantial doubt about the Company's ability to continue as a going concern for at least 12 months from the date of issuance. As of September 30, 2024, cash was $1.9M, and the company expects to continue incurring net losses. Additional funding is required to sustain operations.
- Capital Raising Activities:
- April Public Offering: Raised approx. $6.1M gross proceeds.
- May Inducement Offer: Raised $2.1M via warrant exercises at reduced prices.
- Subscription Agreement (July): Raised $1.0M from a related party.
- Subsequent Events (Oct 2024): Entered into an At-The-Market (ATM) agreement for up to $5.1M and a registered direct offering raising approx. $2.1M.
- Reverse Stock Split: A 1-for-10 reverse stock split was effected on July 15, 2024. All share and per-share data in the filing have been retroactively restated.
- Legal Proceedings: The company is defending against a lawsuit filed by a former Chief Accounting Officer/Interim CFO alleging constructive discharge and defamation. Additionally, a settlement was reached with certain physicians regarding stock option disputes, involving the issuance of restricted shares and warrants.
- Unusual Items: The Q3 2024 net loss includes a deemed dividend of $1.7M related to the May Inducement Offer, which reduced the net loss attributable to common stockholders.
Investor Verification Checklist
- Liquidity Runway: Verify the sufficiency of the $2.1M raised in October 2024 and the $5.1M ATM facility to cover the projected operating burn rate and debt maturities.
- Debt Maturities: Review the schedule of debt maturities, noting significant principal payments due in 2025 ($2.4M) and the terms of related-party notes with high interest rates (up to 24% historically, amended to 14% for some).
- Dilution Risk: Assess the impact of outstanding warrants (approx. 7.3M shares) and options (approx. 0.9M shares) on future share count, especially given the low exercise prices of recent warrant series.
- Clinical Milestones: Monitor progress on the Phase 1b trial for NNV1 (expected Q1 2025) and the planned Phase 1 trial for SNV1 (expected H1 2025), as these are critical for future funding and valuation.
- Related Party Transactions: Scrutinize the terms of debt and equity transactions with related parties, including the CEO and directors, which constitute a significant portion of the capital structure.